Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
English
Regional settings
Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)
Why Capital.com?
About us
Our history
Our offices
Leadership team
Client funds
How Capital.com makes money
Contact us
Terms and policies
Ways to trade
CFD trading
Spread betting
1X
Charges and fees
Professional
Margin Calls
Markets
Shares
Forex
Indices
Commodities
Trading platforms 
Web platform
Mobile apps
MT4
TradingView
Demo
Learn to trade
Essentials of trading
Risk-management guide
Market guides
Trading Strategies
Trading Psychology
Technical analysis
Market analysis
Help
My account

HomeMarketsSharesNovavax Inc

Trade Novavax Inc - NVAX CFD

SummaryHistorical Data
Trading Conditions
Spread0.15
Long position overnight fee
Long position overnight fee
Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
-0.026179 %
(-US$1.05)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00

-0.026179%
Short position overnight fee
Short position overnight fee
Margin. Your investment
US$1,000.00
Overnight fee
Charges from full value of position
0.003957 %
(US$0.16)

Trade size with leverage ~ US$5,000.00

Short position overnight fee ~ US$4,000.00

0.003957%
Overnight fee time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin20
Stock exchangeUnited States of America
Commission on trade10%

Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close4.07
Open4.08
1-Year Change-48.87%
Day's Range3.91 - 4.12

Novavax Company profile

Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases. 

Headquartered in Maryland, United States, the company was founded in 1987.

It has developed a number of vaccines, including:

  • The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.

  • The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.

  • The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).

  • The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials. 

The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis. 

The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB. 

Navavax’s key partners and collaborators include:

  • The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate. 

  • The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).

  • The Serum Institute of India (SII).

  • The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates. 

The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.